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BACKGROUND: Clinical inertia, provider failure to
appropriately intensify treatment, is a major contributor to uncontrolled blood pressure (BP). Some clinical
inertia may result from physician uncertainty over the
patient’s usual BP, adherence, or value of continuing
efforts to control BP through lifestyle changes.
OBJECTIVE: To test the hypothesis that providing
physicians with uncertainty reduction tools, including
24-h ambulatory BP monitoring, electronic bottle cap
monitoring, and lifestyle assessment and counseling,
will lead to improved BP control.
DESIGN: Cluster randomized trial with five intervention
clinics (IC) and five usual care clinics (UCC).
SETTING: Six public and 4 private primary care clinics.
PARTICIPANTS: A total of 665 patients (63 percent
African American) with uncontrolled hypertension
(BP ≥140 mmHg/90 mmHg or ≥130/80 mmHg if
diabetic).
INTERVENTIONS: An order form for uncertainty reduction tools was placed in the IC participants’ charts before
each visit and results fed back to the provider.
OUTCOME MEASURES: Percent with controlled BP at last
visit. Secondary outcome was BP changes from baseline.
RESULTS: Median follow-up time was 24 months. IC
physicians intensified treatment in 81% of IC patients
compared to 67% in UCC (p<0.001); 35.0% of IC
patients and 31.9% of UCC patients achieved control
at the last recorded visit (p>0.05). Multi-level mixed
effects longitudinal regression modeling of SBP and
DBP indicated a significant, non-linear slope difference favoring IC (p time × group interaction =0.048 for SBP
and p =0.001 for DBP). The model-predicted difference attributable to intervention was −2.8 mmHg for
both SBP and DBP by month 24, and −6.5 mmHg for
both SBP and DBP by month 36.
CONCLUSIONS: The uncertainty reduction intervention did not achieve the pre-specified dichotomous
outcome, but led to lower measured BP in IC patients.
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INTRODUCTION
Hypertension is a major risk factor for cardiovascular morbidity
and mortality. While the most recent findings from national
health surveys indicate a marked improvement in hypertension
control over the past decade, 31% of persons treated with drugs
for hypertension are still above the treatment goal of 140/
90 mmHg recommended by the Joint National Committee on
Detection, Evaluation, and Treatment of High Blood Pressure for
individuals without serious cardiovascular co-morbities1,2.
Both individual and patient-level factors have been
proposed to explain the residual lack of blood pressure
(BP) control in treated patients. There is limited evidence
that individual behaviors, such as appointment-keeping or
medication adherence, are the most significant contributors
to poor BP control. National health survey data show that
the great majority of the uncontrolled are insured and have
frequent health care visits3, and objective data indicate that
most patients with uncontrolled BP are actually compliant
with medications4. Berlowitz et al.5 and Rose et al.6 have
documented that poorly controlled BP in treated patients is
largely attributable to physicians’ failure to intensify treatment when confronted with BP measurements that are only
modestly above the recommended control thresholds.
The term “clinical inertia”7 has been coined to refer to
physicians’ failure to intensify treatment according to clear
clinical practice guidelines. In hypertension management,
clinical inertia was operationalized by O’Conner as an office
visit in which no therapeutic action was taken to lower the BP
of a patient with uncontrolled hypertension8. While instances
of clinical inertia are generally viewed as undesirable, growing evidence suggests that it might be rooted in a legitimate
uncertainty over the need for treatment intensification.
Recent studies suggest that the major sources of uncertainty
in hypertension management center on whether the BP
recorded at the visit is representative of the patient’s usual
BP, and whether the patient is actually adherent to the
currently prescribed regimen9,10. In past surveys, physicians
413
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openly disagreed with the recommended target BP11, but this
was not given as a reason not to titrate in the more recent
evaluations cited above.
African Americans (AAs) have both a disproportionately higher
prevalence and higher burden of complications from hypertension, compared to non-Hispanic whites (NHW) in the US12.
Although awareness and treatment of hypertension and selfreported lifestyle actions to control hypertension are now greater
in AAs than NHW, the proportion of AAs controlled on treatment
still remains significantly lower than NHWs1,12–14. There is no
evidence that clinical inertia is significantly different when
treating AAs than hypertensives from other racial/ethnic
groups15,16. However, because of their increased risk for complications of poorly controlled hypertension, it is important that AAs
be well represented in evaluations of new treatment approaches.
We designed a clinic-level intervention to reduce physician
uncertainty about the patient’s actual typical BP, actual adherence to medications, and likelihood of achieving BP control
through lifestyle changes. We hypothesized that reducing physician uncertainty would counteract clinical inertia and lead to
improved blood pressure control. In this paper, we report on the
primary BP control outcomes of this intervention carried out in
ten clinics with substantial numbers of AA patients.
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changes, including weight loss and sodium restriction, have long
been considered important elements of a hypertension control
regimen2,21. In focus groups conducted to develop lifestyle
counseling messages in a previous study, we found that participants assigned considerable value to controlling BP through nonpharmacological means20; thus, we considered it likely that some
instances of clinical inertia occur when patients request more
time to implement intended lifestyle changes.

Participant Inclusion Criteria
Details of the inclusion and exclusion criteria have been
reported previously17. Research assistants identified potential
study participants by screening the medical records of patients
who presented for a routine primary care appointment. Patients
had to have at least two clinic visits in the previous 12 months,
with BP on the most recent two consecutive visits of ≥140 mmHg
systolic or ≥ 90 mmHg diastolic, or if diabetic, ≥ 130 systolic or
80 mmHg diastolic. Patients with cognitive impairment, renal
insufficiency, or a serious concomitant illness such as cancer,
recent MI, or unstable angina, were excluded. Informed consent
was obtained from both the patient and provider.

Outcome Measures
METHODS
Design Overview
The details of this cluster randomized trial have been
reported previously17. Ten primary care clinics belonging to
two different health care systems served as the units of
intervention. Five clinics (ICs) were randomized to implement the uncertainty reduction intervention, and the
remaining clinics served as usual care clinics (UCCs). Six
of the clinics belonged to a public health care delivery
system, and four of the clinics were part of a large, multispecialty group practice. All participating physicians were
general internists or family physicians. Randomization of
clinics to intervention or control condition was stratified by
system. Before randomization, the physicians in all ten
clinics received a baseline knowledge survey and a comprehensive 2-h educational program regarding the JNC 7
treatment guidelines, effective patient-physician communication, and special considerations for treating AAs.
In the ICs, study research staff placed an updated graph of
recent BP measurements in the patient chart before each visit,
along with a referral form to order: (1) 24-h ambulatory BP
monitoring (ABPM), (2) electronic bottle cap assessment of
medication adherence, followed by medication adherence
counseling in non-adherent patients, and (3) lifestyle assessment and counseling followed by 24-h ABPM approximately 3
months after completion of the counseling protocol. The study
staff carried out these procedures and fed back the results to
the ordering physician. The physicians could order any
combination of the tools at any visit. The tools were not
provided in the five clinics assigned to UCC.
We included the assessment of dietary and physical activity
habits18,19, followed by a telephone-based behavioral counseling
program developed for a previous intervention20, because lifestyle

The defined primary endpoint was the proportion of patients with
clinic BP <140/90 mmHg (<130/80 if the patient had diabetes) at
the last visit. Actual change in measured clinic systolic and
diastolic BP from baseline was the secondary endpoint. The
planned duration of follow-up was 2 to 3 years, depending on
randomization date. At each visit we collected data on the number
and class of anti-hypertensive drugs prescribed and whether
treatment was intensified. Intensification was defined as an
increase in the dose of an existing drug or the addition of a drug.

Sample Size
We powered the study for a difference in proportion controlled
of 30% in the control clinics vs. 50% in the intervention clinics
using sample size adjustments to account for the cluster
randomized design22. The effect size assumed a temporal
improvement in BP control in the control clinics. The required
sample size to detect this effect size with alpha=0.05 (twosided) and power of 0.90, an intra-class correlation of 0.008 (to
account for the cluster design) was 160 per group. We
increased this number to 335 per group (670 total) to allow
for an expected 20% attrition over 2 years of follow-up and to
allow for 40% of the sample to consist of non-African Americans while providing sufficient power to examine the effects in
African Americans as a subgroup of interest.

Statistical Analysis
We used an intention-to-treat analysis in which all patients
enrolled, and who did not request to be withdrawn from the
study, were included in the analysis. We first examined the
raw unadjusted changes in proportion of patients controlled
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and changes in SBP and DBP using standard two-group
comparisons (chi-square or independent samples t-test). However, to adjust for clustering, an unbalanced number of
observations within patients and clinics, and a relatively long
planned follow-up time, our principal, analytic approach was
to use multi-level, mixed effects, longitudinal linear and
logistic regression models to assess the intervention effect23,24.
In this approach, the test for differences in the slope of change
in outcomes between the intervention and control groups,
expressed as a time by outcome interaction term, accounts for
any difference in baseline values. Because patients could be
seen by different providers at the clinic at different times, it
was not possible to also account for individual provider effects.
We conducted additional linear and logistic regression analyses to explore the relationship between intervention uptake
and outcomes.
The endpoint for each patient was defined as the clinic BP
recorded on their last visit during the study follow-up period.
In the mixed effects regression models, we expressed follow-up
time as number of months from the baseline visit. The fixed
effects in the models were patient’s baseline characteristics
including age, sex, race, education, and presence or absence of
diabetes. In the model specification for random effects,
patients were nested within clinic and BP measurements
within patients. We fitted models with a random intercept for
clinic effects and a random intercept and slope for patient-level
effects. The structure of the covariance matrix for withinpatient BP change was selected after testing a number of
possible alternatives, including autoregressive and spatial.
Based on the AIC fit statistic and the correlation of slope of
BP change with time, we fit the models with an unstructured
covariance for the patient-specific intercepts and slopes. To
account for possible non-linear BP change, we tested models
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that included a quadratic term for follow-up months. We
selected the final models with a quadratic trend based on
improvement in fit statistics. Analyses were performed using
STATA version 10 and SAS 9.2.

RESULTS
Figure 1 reflects the number of patients screened, enrolled,
and included in the analysis. Recruitment occurred between
January 2006 and March 2007. By chance, the clinic with the
smallest total population was assigned to the intervention
condition and had fewer uncontrolled hypertensives than
expected. As a result, there were slightly more patients in the
UCCs than the ICs.
Table 1 describes the characteristics of the patients in the
ICs compared to the UCCs. The two groups were balanced with
regard to age, race/ethnicity, education, BMI, and prevalence
of type 2 diabetes. However, fewer patients in the ICs were
male (25.9% compared to 37.1%) and employed (44.8%
compared to 53.0%), and more patients in the ICs were
smokers (34.5% compared to 25.4%). Baseline clinic SBP and
DBP were higher in the IC patients.
Table 2 presents a set of process measures that reflect the
average amount of follow-up time accrued by intervention and
control group patients, the number of hypertensive treatment
intensifications ordered by physicians in both groups, and the
number of uncertainty reduction interventions ordered by
physicians in the intervention group clinics over the course of
the study. Eighty percent of patients had four or more visits,
and the difference in number of clinic visits and follow-up time

Figure 1. Consort diagram. Patients were included in the analysis until death or censoring at their last recorded visit. Five deaths occurred in
intervention patients (1 at 9 months and 4 after>12 months of follow-up), and 8 death occurred in the control group (all after >12 months of
follow-up).
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Table 1. Patient Characteristics at Baseline

Age (years, mean±SD)
Sex (% male)
Public clinic patients
Race/ethnicity
Black/African American
Hispanic
Non-Hispanic White
Other
Employment status
Employed
Not working
Retired
Education
Less than high school
High school or GED
Some college and above
Body mass index (mean±SD)
Diabetes (%)
Current smoker (%)*
Systolic blood pressure (mmHg)
Diastolic blood pressure (mmHg)
Number of antihypertensives in regimen

ICs

UCCs

Total*

(n=320)

(n=345)

(n=665)

p

55.03±10.3
83 (25.9)
221 (69.1)
N/A
204 (63.9)
85 (26.6)
27 (8.5)
4 (1.3)
N/A
143 (44.8)
115 (36.1)
61 (19.1)
N/A
105 (33.4)
80 (25.5)
129 (41.1)
34.57±7.74
150 (46.9)
108 (34.5)
150.22±20.34
85.83±3.50
2.02±1.26

55.2±10.6
128 (37.1)
207 (60.0)
N/A
216 (64.0)
87 (25.2)
34 (9.9)
8 (2.3)
N/A
183 (53.0)
83 (24.1)
79 (22.9)
N/A
105 (30.5)
105 (30.5)
134 (39.0)
34.23±7.81
181 (52.5)
87 (25.4)
145.41±18.93
83.23±13.11
1.91±1.38

55.2±10.5
211 (31.7)
428 (64.4)
N/A
420 (63.3)
172 (25.9)
61 (9.2)
12 (1.8)
N/A
326 (49.1)
198 (29.8)
140 (21.1)
N/A
210 (31.9)
185 (28.1)
263 (40.0)
34.39±7.77
331 (49.8)
195 (29.7)
147.73±19.75
84.48±13.35
1.96±1.32

0.890
0.002
0.015
0.600
N/A
N/A
N/A
N/A
0.003
N/A
N/A
N/A
0.348
N/A
N/A
N/A
0.566
0.150
0.011
0.002
0.012
0.318

*Some variables have a small number of missing values

to UCC patients in Table 3. As dictated by the eligibility
criteria, all patients were uncontrolled at baseline. The proportion defined as controlled at their last observed clinic visit
was 35.0% in the intervention group and 31.9% in the control
group, a difference that was not statistically significant.
However, the reduction in clinic SPB and DBP was significantly
greater in intervention clinic patients than control clinic
patients.
In mixed-effects logistic regression modeling, the dichotomous outcome remained non-significant. The modeling of
SBP and DBP as continuous variables indicated that the
slope of both SBP and DBP was best described with a

was not significantly different in the intervention and control
groups. Table 2 also reports the use of uncertainty reduction
tools by the physicians in the intervention arm. Overall, 40% of
patients were referred for one or more of the uncertainty
reduction interventions. Of those referred for ABPM, 24% were
found to be controlled out of office. Of those referred for
electronic bottle cap monitoring, 71% were compliant. The
majority of patients referred for lifestyle assessment needed
counseling on reduction of dietary sodium, increase in fruit
and vegetable consumption, and increased physical activity.
We report the raw, unadjusted changes in overall BP
control, and in clinic SBP and DBP in IC patients compared

Table 2. Follow-up Time, Treatment Intensification and Intervention Exposure by Number of Clinic Follow-up Visits
Number of visits
to clinic

1
2–3
4–5
6–9
≥10
Column total or
overall mean
*

Number (%) of
patients

Follow-up time
(months)*

Number of treatment
intensifications (dose
increase or addition
of a drug)†

Number (%) of patients referred for an
uncertainty reduction intervention
(intervention group only)‡

IC

UCC

IC

UCC

IC

UCC

ABPM§

17
59
65
142
62
345

0
11.8±9.3
17.9±8.7
22.7±5.1
24.5±4.2
19.8±8.7

0
12.9±10.3
16.9±7.7
23.5±5.2
24.9±4.5
19.5±9.1

0.5±0.52
0.9±0.77
1.3±1.0
1.7±1.2
2.8±2.1
1.8±1.5

0.3±0.5
0.6±0.6
0.9±0.8
1.3±1.3
2.2 ±1.7
1.3±1.5

1
6
10
29
26
72

14
36
60
117
84
320

(4)
(11)
(19)
(37)
(26)

(5)
(17)
(19)
(41)
(18)

(7)
(17)
(17)
(25)
(31)
(23)

MEMS ||

0
5
8
31
26
70

(14)
(13)
(25)
(31)
(22)

p=09 for overall mean follow-up months
p<0.001 for overall mean difference
‡Denominator for percents=320
§25% controlled
||71% adherent (≥80% of prescribed doses taken)
¶45 (53%) had high fat diet pattern; 76(89%) had low fruit/vegetable intake; 60 (71%) had sedentary lifestyle; 18 (21%) smoked

†

Lifestyle¶

0
8 (22)
14 (23)
32 (27)
31 (37)
85 (27)

Any
Referral
1
12
19
57
42
131

(27)
(31)
(49)
(50)
(40)
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Table 3. Unadjusted Changes in Blood Pressure Control in
Intervention and Control Group Patients

Defined control
(percent)
Change in SBP
(mean±SD)
Change in DBP
(mean±SD)

IC

UCC

p

35.0

31.9

0.395

−10.02 ±24.67

−4.60±22.87

0.003

−5.34±14.33

−0.49±13.62

<0.001
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1.24, 95% CI 0.99, 1.56 for the DBP model). AAs had
significantly higher SBP and DBP than non-AAs throughout
the follow-up period, and our longitudinal modeling did not
show a significantly different rate of BP change in AAs.
Adverse events, including ER visits and hospitalizations for
cardiovascular and non-cardiovascular causes, were similar
in the IC and UCC groups.

*p values are for the comparison between change values for intervention
and control clinic patients. A simple independent samples chi-square test
was used to test the difference in proportion controlled at last visit, and
the independent samples t-test was used to test mean change in SBP
and DBP

quadratic trend over time, which favored lower BPs in ICs
compared to UCCs. The graphs in Figure 2 indicate that
during the early months of the intervention, SBP and DBP
declined in both intervention and control clinics. After
approximately 18 months, both SBP and DBP began to
rise in UCCs but not ICs. By 36 months, the modelpredicted SBP and DBP were 6.5 mmHg lower in ICs than
UCCs. (The equivalence of this difference is coincidental,
with results from the coefficient for group by time squared
interaction being the same for SBP and DBP). Additional
details on modeling results and predicted differences are
provided in the appendix material (accessible online). Since
providers in ICs chose to order one or more intervention
tools for only 40% of enrolled patients, we examined the
effects of exposure to the intervention within ICs. As
shown in Figure 3, patients referred for monitoring or
lifestyle assessment and counseling had higher baseline
BPs that improved significantly compared to patients not
referred. Because of the large proportion of patients who
received more than one uncertainty reduction procedure
simultaneously, we cannot assess the impact of each tool
individually.
To determine whether the BP reduction in ICs could be
attributed to treatment intensification, we constructed
longitudinal logistic regression models to calculate the odds
ratio (OR) for adding a drug or increasing a drug dosage in
ICs compared to UCCs. Adjusting for SBP at the encounter,
the OR for treatment intensification in ICs vs. UCCs was
1.29 (95% CI=1.10–1.51, p=0.001), and adjusting for DBP
at the encounter, the OR was 1.35 (95% CI=1.14–1.50, p≤
0.001). In mixed models associating longitudinal changes in
SBP and DBP with the number of treatment intensifications, a greater number of treatment intensifications was
significantly associated with lower SBP over time (beta for
the number of intensifications by follow-up months interaction=-0.078, p≤ 0.001). The interaction term in the DBP
model did not reach statistical significance (beta=-0.02, p=
0.085). The absolute probability of a treatment intensification was strongly related to BP at the visit; in ICs, treatment
intensification occurred in 24% of encounters where SBP
was in the 140–149 mmHg range, 34% where SBP was in
the 150–159 mmHg range, and 41% of encounters when
SBP≥ 160 mmHg. Presence of diabetes was not associated
with the probability of treatment intensification in the ICs
(OR=1.01, 95% CI=0.81, 1.25 for the SBP model, and OR=

Figure 2. Systolic and diastolic blood pressure trend in intervention
compared to control clinics. Systolic blood pressure (SBP) and
diastolic blood pressure (DBP) trends in intervention and control
clinics predicted from the mixed effects models. The SBP prediction
equation was: 141.48 + 070 (age) - 1.738 (sex)+2.540 (black) 0.658 (follow-up month) + 2.291(group assignment)+0.020 (followup month squared) - 0.005 (follow-up month squared * group
assignment). The DBP prediction equation was: 110.03 - 0.393 (age)
- 3.786 (sex)+3.215 (black) - 2.577 (diabetes) - 0.256 (follow-up
month)+0.1.026 (group assignment)+0.010 (follow-up month
squared) - 0.005 (follow-up month squared * group assignment).
Education, smoking, and health system were not significant predictors of SBP or DBP change, and were omitted from final models
to preserve degrees of freedom. Diabetes was not associated with
SBP change. The p-values for (months squared × group) interaction
term were 0.048 and 0.001 for the SBP and DPB models, respectively. The model-predicted difference in SBP in the intervention
group compared to the control group is -0.749 mmHg at 12 months,
-3.00 mmHg at 24 months, and −6.48 mmHg at 36 months. The
model predicted difference in DBP in the intervention group
compared to the control group is -0.720 mmHg at 12 months,
-2.88 mmHg at 24 months, and -6.48 mmHg at 36 months.
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Figure 3. Blood pressure trend in patients referred for any uncertainty reduction intervention compared to patients never referred
(intervention clinics only). SBP trend in patients referred for any
uncertainty reduction intervention compared to patients never
referred in the intervention clinics. The mixed effects linear
regression coefficient associated with referral was 5.70±1.70
(p<0.001), and the coefficient for the interaction of referral by
follow-up month was -0.21±0.11 (p=0.048).

DISCUSSION
This clinic-level intervention did not achieve the pre-specified
difference in proportion of initially uncontrolled hypertensives
who reached the threshold of <140/90 mmHg (130/80 mmHg
if diabetic). However, it was clear that patients in intervention
clinics had a significantly different trajectory of measured BP
change over time that supported an effect of the uncertainty
reduction tools in BP management. Process measures, including evidence of more aggressive drug titration, and a significant
decline in BP in patients within the ICs who were referred for
monitoring and counseling, supported the hypothesis that
reducing uncertainty about the need for treatment intensification would help to overcome clinical inertia and thereby lead to
better BP control. In addition, the finding that 25% of patients
referred for ABPM had adequate BP control and 30% of
monitored patients were non-adherent to medications suggests that clinician uncertainty over the need to intensify
treatment is often warranted.
Despite the significantly lower BP achieved in ICs compared
to UCCs over time, hypertension control as a categorical
construct did not improve. Several factors may have limited
the categorical effect size. To maximize acceptance by providers
and generalizability, our intervention left the decisions regarding which patients to refer for monitoring and/or counseling,
and which management actions to take after receiving the
results to the individual providers. Our baseline educational
program stressed the importance of treating BP to less than
140/90 mmHg (130/80 mmHg), and in the knowledge and
attitudes survey that preceded the educational session, over
90 percent of providers reported that they sought these targets
in their practices. However, the trend line in Figure 3 and
evidence that treatment intensifications were relatively unlikely when SBP was less than 150 mmHg indicate clearly that
providers’ real threshold for an action to lower SBP was closer

JGIM

to 150 mmHg. Since the mean baseline BP was higher in ICs
than UCCs, the BP lowering achieved with uncertainty reduction tools did not translate to the expected difference in
categorically defined control. Finally, physicians did not act
aggressively to reach the lower recommended treatment
targets in the large number of patient with diabetes who
qualified for the study with SBP ≥130–139 mmHg or
DBP≥80 mmHg.
The clinicians in our system are not unique in failing to
adhere stringently to the recommended treatment goals. A
recent study in North Carolina also found that physicians are
unlikely to take treatment actions when SBP is just above the
140 mmHg line25. The discussion about the appropriate goals
for hypertension management may become more complex with
recent publication of trials that do not clearly support targets
less than 140 mmHg, even in high-risk patients26–28. While
uncertainty reduction tools can help clinicians make a treatment decision, they cannot be expected to change the actual
treatment target.
Our intervention design had both strengths and limitations.
We did not attempt to alter routine care delivery; thus, patients
had variable numbers of visits at variable intervals. Both
clinicians and patients may have had multiple concerns and
were not obligated to address BP control issues at all visits. Many
successful hypertension interventions rely on an additional
provider, such as a nurse or pharmacist, who focuses exclusively
on BP control29. In our study, providers were allowed to make
independent judgments about the value of ordering uncertainty
reduction procedures in a particular patient and the actions that
should be taken after receiving the results. An alternative
approach that has shown substantial BP reductions requires
providers to follow a rigid drug titration protocol to achieve
guideline mandated targets27,30. Although our reliance on providers’ individual decision-making may have attenuated the effect
size, our results are applicable to the large number of practice
settings that do not have a nurse or pharmacist to augment
hypertension management. Many aspects of our intervention
could easily be incorporated into current office practice models,
and all components could be implemented in a team-based
medical home model.
It is encouraging that the magnitude of the intervention effect
was similar in public vs. private clinics, and in AA patients
compared to non-AAs. Nevertheless, the finding that BP levels in
AAs remained higher than in non-AAs exposed to the same
treatment conditions indicates that achieving satisfactory BP
control in AAs remains a challenge.
Baseline BP and group assignment were not related to the
number of follow-up visits or time. Thus, our results are unlikely
to be biased by differential losses to follow-up. However, the
longitudinal modeling results make it clear that patients with a
longer follow-up period were more likely to benefit from the
intervention than those with shorter follow-ups.
In summary, we demonstrated that the introduction of a set
of tools to reduce uncertainty over usual BP and medication
adherence led to significantly lower SBP and DBP in five
intervention clinics compared to clinics where the tools were
not available. Within the ICs, BP was reduced sharply in
patients who were referred for monitoring or lifestyle assessment
and counseling. However, the expectation that a clinic level
intervention in which providers determined when to employ the
uncertainty reduction tools would lead to a 20% difference in
proportion controlled was not met. The study supports our
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hypothesis that reducing uncertainty about the reason patients’
BP is poorly controlled may be an effective strategy to improved
BP control, but additional research on the conditions under
which these tools can be optimally effective is needed.
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